Key women’s health and osteoporosis studies you should know about

The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.

Data from a new study is sounding the alarm on trends in the trajectory of hip fracture incidence among the general population.

Data from a cohort of 5000 patients indicates that NSAID use may negatively affect clodronate therapy in older women.

An analysis of data from a 5000-patient cohort suggests use of NSAIDs was associated with a detrimental effect on the benefit of clodronate on reducing risk of fracture among older women.

A study in the journal Vascular Health and Risk Management has found significant differences in the metabolite profiling of altered amino acid and lipoprotein metabolism in participants with atherosclerosis and osteoporosis, compared with those in healthy menopausal women.

A European multicenter clinical study that evaluated the diagnostic accuracy of radiofrequency echographic multi-spectrometry (REMS) for osteoporosis has concluded that both REMS sensitivity and specificity are over 90%, when using the current clinical reference technology of dual-energy x-ray absorptiometry (DXA).